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Adenosine deaminase acting on RNA (ADAR1) is a RNA-editing enzyme that converts 
adenosine into inosine, resulting in alterations of the RNA sequence and subsequent 
downstream effects. It has been shown to be over-expressed in a variety of cancers 
including breast cancer but its exact role in tumorigenesis remains unclear. To better 
understand the effects of ADAR1 on breast cancer tumorigenesis, we generated shRNA-
containing lentiviruses to knock-down the expression of ADAR1 in human breast cancer 
cell lines. We performed Western blot analysis to verify the successful knock-down of 
ADAR1 protein. We conducted focus formation assay to test the effect of ADAR1 knock-
down on human breast cancer cell lines’ proliferative abilities. We also performed scratch 
assay to test the metastatic potential of the same cell lines.
ADAR1 expression was successfully downregulated in all of the human breast cancer 
cell lines we tested. Interestingly, downregulation of ADAR1 reduced proliferation 
of triple-negative breast cancer (TNBC) cell lines while having little effect on the 
proliferation of non-TNBC cell lines. Scratch assay also revealed the downregulation 
of ADAR1 inhibited the migratory abilities of TNBC cell lines. These results suggest 
that ADAR1 is a key player in the oncogenic nature of TNBC. We are in the process of 
performing in vivo mouse studies to verify our findings from the cell culture system and 
to develop an animal model for future development of potential innovative treatment 
options. Further investigation promises to illuminate novel targeted therapeutic 
approaches currently lacking in the treatment of TNBC.
